Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Abstract: This invention pertains to compounds having the structure: wherein m is 0, 1, 2, or 3; R2 is a substituted or unsubstituted imidazole or pyrazole wherein the point of attachment of R2 to the alkyl chain is not N; R5 is a hydrogen atom or a substituted or unsubstituted alkyl, aryl, or alkylaryl moiety; and R7 is a halogen atom, C1-C4 alkyl, OH, O-alkyl(C1-C4), NH2, or NH-alkyl(C1-C4), which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compound.